FDA will likely pull epinephrine inhalers (Primatene Mist, etc) off the market

March 2006

FDA will likely pull epinephrine inhalers (Primatene Mist, etc) off the market.

FDA advisors now say that OTC epinephrine inhalers DON'T offer an important health benefit...and SHOULDN'T be exempt from the ban on CFC propellants.

Wyeth is trying to reformulate Primatene Mist. But it could take 5 years for the new version to be tested and approved.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

MedGuides are piling up on many pharmacy counters
Cardiology Ranexa (ranolazine) for chronic angina
Cardiology LOW-dose vitamin K supplements to stabilize the effect of warfarin in certain patients
Osteoporosis IV form of Boniva (ibandronate)
whether saw palmetto is effective for benign prostatic hyperplasia (BPH)
American Heart Association now says NOT to rely on soy protein or isoflavone supplements to prevent heart disease
Diabetes whether sulfonylureas increase mortality
Diabetes Many patients are looking forward to trying the new inhaled insulin, Exubera
Diabetes Apidra (insulin glulisine) is the newest rapid-acting insulin
Statins how to monitor for myopathy in patients taking statins
FDA will likely pull epinephrine inhalers (Primatene Mist, etc) off the market
Kidney Disease Even patients with SEVERE kidney disease seem to benefit from ACE inhibitors
Obesity & Weight Loss Acomplia and OTC orlistat for weight loss
Infectious Diseases possible liver toxicity in patients taking Ketek (telithromycin)
Infectious Diseases Tequin (gatifloxacin) is now contraindicated for diabetes patients